ICAM1 and neoplasm: Clinical precedents involving ICAM1‐targeted CAR‐T cells[62] and oncolytic viruses[63] have also demonstrated favorable safety, supporting the feasibility of ICAM1 as a therapeutic target, particularly when paired with tumor‐localized activation strategies such as NIR‐pyroptosis.